Hot flash therapies in breast cancer survivors

Supportive Cancer Therapy

Volumn 4, Issue 1, 2006, Pages 38-48

  Chang, Yuan Ching ^a,b,c   Parker, Jeanene ^a   Dooley, William C ^a  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^b MACKAY MEMORIAL HOSPITAL   (Taiwan)

^c NURSING AND MANAGEMENT COLLEGE   (Taiwan)

Author keywords

Antidepressants; Belladonna; Clonidine; Gabapentin; Hormonal therapy; Methyldopa; Nonhormonal therapy

Indexed keywords

ALPHA TOCOPHEROL; ANTIDEPRESSANT AGENT; BELLERGAL; CIMICIFUGA RACEMOSA EXTRACT; CITALOPRAM; CLONIDINE; DRUG METABOLITE; ENDOXIFEN; ESTROGEN; FLUOXETINE; GABAPENTIN; ISOFLAVONE DERIVATIVE; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; METHYLDOPA; MIRTAZAPINE; MOCLOBEMIDE; PAROXETINE; PROGESTERONE; SERTRALINE; SERUM ALBUMIN; TAMOXIFEN; TIBOLONE; UNCLASSIFIED DRUG; VENLAFAXINE; VERALIPRIDE;

ABNORMALLY LOW SUBSTRATE CONCENTRATION IN BLOOD; ALBUMIN BLOOD LEVEL; APPETITE DISORDER; BREAST CANCER; CANCER DIAGNOSIS; CANCER SURVIVAL; CLINICAL TRIAL; CLUSTER HEADACHE; CONSTIPATION; DIZZINESS; DROWSINESS; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG FORMULATION; DRUG MECHANISM; DRUG TOLERABILITY; EDEMA; FATIGUE; FEMALE; GALACTORRHEA; GASTROINTESTINAL SYMPTOM; HEADACHE; HOT FLUSH; HUMAN; IATROGENIC DISEASE; INSOMNIA; LETHARGY; LIFESTYLE; MASTALGIA; MENOPAUSAL SYNDROME; MIGRAINE; NAUSEA; PATHOGENESIS; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; PRURITUS; REVIEW; SIDE EFFECT; SOMNOLENCE; SWELLING; WEAKNESS; WEIGHT GAIN; XEROSTOMIA;

EID: 33751193220     PISSN: 15432912     EISSN: None     Source Type: Journal    
DOI: 10.3816/SCT.2006.n.030     Document Type: Review

References (104)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56:106-130.
2. Carpenter JS, Andrykowski MA, Cordova M, et al. Hot flashes in post-menopausal women treated for breast carcinoma: prevalence, severity, correlates, management, and relation to quality of life. Cancer 1998; 82:1682-1691.
3. Bachmann GA. Vasomotor flushes in menopausal women. Am J Obstet Gynecol 1999; 180:S312-S316.
4. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365:1687-1717.
5. Gold EB, Sternfeld B, Kelsey JL, et al. Relation of demographic and lifestyle factors to symptoms in a multi-racial/ethnic population of women 40-55 years of age. Am J Epidemiol 2000; 152:463-473.
6. Finck G, Barton DL, Loprinzi CL, et al. Definitions of hot flashes in breast cancer survivors. J Pain Symptom Manage 1998; 16:327-333.
7. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288:321-333.
8. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004; 291:1701-1712.
9. Fellowes D, Fallowfield LJ, Saunders CM, et al. Tolerability of hormone therapies for breast cancer: how informative are documented symptom profiles in medical notes for 'well-tolerated' treatments? Breast Cancer Res Treat 2001; 66:73-81.
10. Freedman RR. Pathophysiology and treatment of menopausal hot flashes. Semin Reprod Med 2005; 23:117-125.
11. Deecher DC. Physiology of thermoregulatory dysfunction and current approaches to the treatment of vasomotor symptoms. Expert Opin Investig Drugs 2005; 14:435-448.
12. Freeman EW, Sammel MD, Grisso JA, et al. Hot flashes in the late reproductive years: risk factors for Africa American and Caucasian women. J Womens Health Gend Based Med 2001; 10:67-76.
13. Schwingl PJ, Hulka BS, Harlow SD. Risk factors for menopausal hot flashes. Obstet Gynecol 1994; 84:29-34.
14. Gold EB, Block G, Crawford S, et al. Lifestyle and demographic factors in relation to vasomotor symptoms: baseline results from the Study of Women's Health Across the Nation. Am J Epidemiol 2004; 159:1189-1199.
15. Smith-Warner SA, Spiegelman D, Yaun SS, et al. Alcohol and breast cancer in women: a pooled analysis of cohort studies. JAMA 1998; 279:535-540.
16. Michnovicz JJ, Hershcopf RJ, Naganuma H, et al. Increased 2-hydroxylation of estradiol as a possible mechanism for the anti-estrogenic effect of cigarette smoking. N Engl J Med 1986; 315:1305-1309.
17. Cassidenti DL, Vijod AG, Vijod MA, et al. Short-term effects of smoking on the pharmacokinetic profiles of micronized estradiol in postmenopausal women. Am J Obstet Gynecol 1990; 163:1953-1960.
18. Li C, Samsioe G, Borgfeldt C, et al. Menopause-related symptoms: what are the background factors? A prospective population-based cohort study of Swedish women (the Women's Health in Lund Area study). Am J Obstet Gynecol 2003; 189:1646-1653.
19. Whiteman MK, Staropoli CA, Langenberg PW, et al. Smoking, body mass, and hot flashes in midlife women. Obstet Gynecol 2003; 101:264-272.
20. Terry PD, Rohan TE. Cigarette smoking and the risk of breast cancer in women: a review of the literature. Cancer Epidemiol Biomarkers Prev 2002; 11:953-971.
21. Morabia A. Smoking (active and passive) and breast cancer: epidemiologic evidence up to June 2001. Environ Mol Mutagen 2002; 39:89-95.
22. Santella RM, Gammon MD, Zhang YJ, et al. Immunohistochemical analysis of polycyclic aromatic hydrocarbon-DNA adducts in breast tumor tissue. Cancer Lett 2000; 154:143-149.
23. Conway K, Edmiston SN, Cui L, et al. Prevalence and spectrum of p53 mutations associated with smoking in breast cancer. Cancer Res 2002; 62:1987-1995.
24. Terry PD, Goodman M. Is the association between cigarette smoking and breast cancer modified by genotype? A review of epidemiologic studies and meta-analysis. Cancer Epidemiol Biomarkers Prev 2006; 15:602-611.
25. Harber VJ, Sutton JR, MacDougall JD, et al. Plasma concentrations of beta-endorphin in trained eumenorrheic and amenorrheic women. Fertil Steril 1997; 67:648-653.
26. Rebar RW, Spitzer IB. The physiology and measurement of hor flushes. Am J Obstet Gynecol 1987; 156:1284-1288.
27. Freedman RR. Core body temperature variation in symptomatic and asymptomatic postmenopausal women: brief report. Menopause 2002; 9:399-401.
28. Aiello EJ, Yasui Y, Tworoger SS, et al. Effect of a yearlong, moderate-intensity exercise intervention on the occurrence and severity of menopause symptoms in postmenopausal women. Menopause 2004; 11:382-388.
29. Li S, Holm K. Physical activity alone and in combination with hormone replacement therapy on vasomotor symptoms in postmenopausal women. West J Nurs Res 2003; 25:274-288; discussion 289-293.
30. Ivarsson T, Spetz AC, Hammar M. Physical exercise and vasomotor symptoms in postmenopausal women. Maturitas 1998; 29:139-146.
31. Holmes MD, Chen WY, Feskanich D, et al. Physical activity and survival after breast cancer diagnosis. JAMA 2005; 293:2479-2486.
32. Freedman RR, Woodward S. Behavioral treatment of menopausal hot flushes: evaluation by ambulatory monitoring. Am J Obstet Gynecol 1992; 167:436-439.
33. Irvin JH, Domar AD, Clark C, et al. The effects of relaxation response training on menopausal symptoms. J Psychosom Obstet Gynaecol 1996; 17:202-207.
34. Wyon Y, Wijma K, Nedstrand E, et al. A comparison of acupuncture and oral estradiol treatment of vasomotor symptoms in postmenopausal women. Climacteric 2004; 7:153-164.
35. Vincent AB, Mandrekar J, Cha S, et al. Acupunture: efficacy for hot flashes. Gender Med 2006; 3(suppl A):566.
36. Wilbur J, Miller AM, Montgomery A, et al. Sociodemographic characteristics, biological factors, and symptom reporting in midlife women. Menopause 1998; 5:43-51.
37. Demark-Wahnefried W, Peterson BL, Winer EP, et al. Changes in weight, body composition, and factors influencing energy balance among premenopausal breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 2001; 19:2381-2319.
38. Rock CL, Demark-Wahnefried W. Nutrition and survival after the diagnosis of breast cancer: a review of the evidence. J Clin Oncol 2002; 20:3302-3316.
39. Chlebowski RT, Aiello E, McTiernan A. Weight loss in breast cancer patient management. J Clin Oncol 2002; 20:1128-1143.
40. Lebherz TB, French L. Nonhormonal treatment of the menopausal syndrome. A double-blind evaluation of an autonomic system stabilizer. Obstet Gynecol 1969; 33:795-799.
41. Bergmans MG, Merkus JM, Corbey RS, et al. Effect of Bellergal Retard on climacteric complaints: a double-blind, placebo-controlled study. Maturitas 1987; 9:227-234.
42. Freedman RR, Dinsay R. Clonidine raises the sweating threshold in symptomatic but not in asymptomatic postmenopausal women. Fertil Steril 2000; 74:20-23.
43. Goldberg RM, Loprinzi CL, O'Fallon JR, et al. Transdermal clonidine for ameliorating tamoxifen-induced hot flashes. J Clin Oncol 1994; 12:155-158.
44. Pandya KJ, Raubertas RF, Flynn PJ, et al. Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a University of Rochester Cancer Center Community Clinical Oncology Program study. Ann Intern Med 2000; 132:788-793.
45. Nesheim BI, Saetre T. Reduction of menopausal hot flushes by methyldopa. A double blind crossover trial. Eur J Clin Pharmacol 1981; 20:413-416.
46. Hammond MG, Hatley L, Talbert LM. A double blind study to evaluate the effect of methyldopa on menopausal vasomotor flushes. J Clin Endocrinol Metab 1984; 58:1158-1160.
47. Evans ML, Pritts E, Vittinghoff E, et al. Management of postmenopausal hot flushes with venlafaxine hydrochloride: a randomized, controlled trial. Obstet Gynecol 2005; 105:161-166.
48. Loprinzi CL, Kugler JW, Sloan JA, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 2000; 356:2059-2063.
49. Stearns V, Beebe KL, Iyengar M, et al. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA 2003; 289:2827-2834.
50. Stearns V, Slack R, Greep N, et al. Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial. J Clin Oncol 2005; 23:6919-6930.
51. Loprinzi CL, Sloan JA, Perez EA, et al. Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol 2002; 20:1578-1583.
52. Suvanto-Luukkonen E, Koivunen R, Sundstrom H, et al. Citalopram and fluoxetine in the treatment of postmenopausal symptoms: a prospective, randomized, 9-month, placebo-controlled, double-blind study. Menopause 2005; 12:18-26.
53. Loprinzi CL, Flynn PJ, Carpenter LA, et al. Pilot evaluation of citalopram for the treatment of hot flashes in women with inadequate benefit from venlafaxine. J Palliat Med 2005; 8:924-930.
54. Kimmick GG, Lovato J, McQuellon R, et al. Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen. Breast J 2006; 12:114-122.
55. Zichella L, Falaschi P, Fioretti P, et al. Effects of different dopamine agonists and antagonists on post-menopausal hot flushes. Maturitas 1986; 8:229-237.
56. Melis GB, Gambacciani M, Cagnacci A, et al. Effects of the dopamine antagonist veralipride on hot flushes and luteinizing hormone secretion in postmenopausal women. Obstet Gynecol 1988; 72:688-692.
57. David A, Don R, Tajchner G, et al. Veralipride: alternative antidopaminergic treatment for menopausal symptoms. Am J Obstet Gynecol 1988; 158:1107-1115.
58. Tarim E, Bagis T, Kilicdag E, et al. Moclobemide in the treatment of hot flashes in postmenopausal women. Adv Ther 2002; 19:258-265.
59. Barton D, La VB, Loprinzi C, et al. Venlafaxine for the control of hot flashes: results of a longitudinal continuation study. Oncol Nurs Forum 2002; 29:33-40.
60. Perez DG, Loprinzi CL, Barton DL, et al. Pilot evaluation of mirtazapine for the treatment of hot flashes. J Support Oncol 2004; 2:50-56.
61. Barton DL, Loprinzi CL, Novotny P, et al. Pilot evaluation of citalopram for the relief of hot flashes. J Support Oncol 2003; 1:47-51.
62. Goetz MP, Loprinzi CL. A hot flash on tamoxifen metabolism. J Natl Cancer Inst 2003; 95:1734-1735.
63. Stearns V, Johnson MD, Rae JM, et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 2003; 95:1758-1764.
64. Jin Y, Desta Z, Stearns V, et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005; 97:30-39.
65. Goetz MP, Rae JM, Suman VJ, et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 2005; 23:9312-9318.
66. Guttuso TJ Jr. Gabapentin's effects on hot flashes and hypothermia. Neurology 2000; 54:2161-2163.
67. Loprinzi L, Barton DL, Sloan JA, et al. Pilot evaluation of gabapentin for treating hot flashes. Mayo Clin Proc 2002; 77:1159-1163.
68. Guttuso T Jr, Kurlan R, McDermott MP, et al. Gabapentin's effects on hot flashes in postmenopausal women: a randomized controlled trial. Obstet Gynecol 2003; 101:337-345.
69. Pandya KJ, Morrow GR, Roscoe JA, et al. Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. Lancet 2005; 366:818-824.
70. Stefanick ML, Anderson GL, Margolis KL, et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in post-menopausal women with hysterectomy. JAMA 2006; 295:1647-1657.
71. Druckmann R. Progestins and their effects on the breast. Maturitas 2003; 46(suppl 1):S59-S69.
72. Loprinzi CL, Michalak JC, Quella SK, et al. Megestrol acetate for the prevention of hot flashes. N Engl J Med 1994; 331:347-352.
73. Quella SK, Loprinzi CL, Sloan JA, et al. Long term use of megestrol acetate by cancer survivors for the treatment of hot flashes. Cancer 1998; 82:1784-1788.
74. Bertelli G, Venturini M, Del Mastro L, et al. Intramuscular depot medroxyprogesterone versus oral megestrol for the control of post-menopausal hot flashes in breast cancer patients: a randomized study. Ann Oncol 2002; 13:883-888.
75. Loprinzi CL, Levitt R, Barton D, et al. Phase III comparison of depomedroxyprogesterone acerate to venlafaxine for managing hot flashes: North Central Cancer Treatment Group trial N99C7. J Clin Oncol 2006; 24:1409-1414.
76. Muggia FM, Cassieth PA, Ochoa M Jr, et al. Treatment of breast cancer with medroxyprogesterone acetate. Ann Intern Med 1968; 68:328-337.
77. Palmieri D, Halverson DO, Ouatas T, et al. Medroxyprogesterone acetate elevation of Nm23-H1 metastasis suppressor expression in hormone receptor-negative breast cancer. J Natl Cancer Inst 2005; 97:632-642.
78. Landgren MB, Bennink HJ, Helmond FA, et al. Dose-response analysis of effects of tibolone on climacteric symptoms. BJOG 2002; 109:1109-1114.
79. Purohit A, Malini B, Hooymans C, et al. Inhibition of oestrone sulphatase activity by tibolone and its metabolites. Horm Metab Res 2002; 34:1-6.
80. Gompel A, Siromachkova M, Lombet A, et al. Tibolone actions on normal and breast cancer cells. Eur J Cancer 2000; 36(suppl 4):S76-S77.
81. Valdivia I, Campodonico I, Tapia A, et al. Effects of tibolone and continuous combined hormone therapy on mammographic breast density and breast histochemical markers in postmenopausal women. Fertil Steril 2004; 81:617-623.
82. Tang GW. The climacteric of Chinese factory workers. Maturitas 1994; 19:177-182.
83. Limer JL, Speirs V. Phyto-oestrogens and breast cancer chemoprevention. Breast Cancer Res 2004; 6:119-127.
84. Quella SK, Loprinzi CL, Barton DL, et al. Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: a North Central Cancer Treatment Group trial. J Clin Oncol 2000; 18:1068-1074.
85. Albertazzi P, Purdie D. The nature and utility of the phytoestrogens: a review of the evidence. Maturitas 2002; 42:173-185.
86. Farrell E. Medical choices available for management of menopause. Best Pract Res Clin Endocrinol Metab 2003; 17:1-16.
87. Upmalis DH, Lobo R, Bradley L, et al. Vasomotor symptom relief by soy isoflavone extract tablets in postmenopausal women: a multicenter, double-blind, randomized, placebo-controlled study. Menopause 2000; 7:236-242.
88. Faure ED, Chantre P, Mares P. Effects of a standardized soy extract on hot flushes: a multicenter, double-blind, randomized, placebo-controlled study. Menopause 2002; 9:329-334.
89. van de Weijer PH, Barentsen R. Isoflavones from red clover (Promensil) significantly reduce menopausal hot flush symptoms compared with placebo. Maturitas 2002; 42:187-193.
90. Krebs EE, Ensrud KE, MacDonald R, et al. Phytoestrogens for treatment of menopausal symptoms: a systematic review. Obstet Gynecol 2004; 104:824-836.
91. Bodinet C, Freudenstein J. Influence of marketed herbal menopause preparations on MCF-7 cell proliferation. Menopause 2004; 11:281-289.
92. Burdette JE, Liu J, Chen SN, et al. Black cohosh acts as a mixed competitive ligand and partial agonist of the seroronin receptor. J Agric Food Chem 2003; 51:5661-5670.
93. Borrelli F, Ernst E. Cimicifuga racemosa: a systematic review of its clinical efficacy. Eur J Clin Pharmacol 2002; 58:235-241.
94. Wuttke W, Seidlova-Wuttke D, Gorkow C. The Cimicifuga preparation BNO 1055 vs. conjugated estrogens in a double-blind placebo-controlled study: effects on menopause symptoms and bone markers. Maturitas 2003; 44(suppl 1):S67-S77.
95. Hernandez Munoz G, Pluchino S. Cimicifuga racemosa for the treatment of hot flushes in women surviving breast cancer. Maturitas 2003; 44(suppl 1):S59-S65.
96. Jacobson JS, Troxel AB, Evans J, et al. Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer. J Clin Oncol 2001; 19:2739-2745.
97. Pockaj BA, Gallagher JG, Loprinzi CZ, et al. Phase III double-blind, randomized, placebo-controlled crossover trial of black cohosh in the management of hot flashes: NCCTG Trial N01CC1. J Clin Oncol 2006; 24:2836-2841.
98. Huntley A, Ernst E. A systematic review of the safety of black cohosh. Menopause 2003; 10:58-64.
99. Lontos S, Jones RM, Angus PW, et al. Acute liver failure associated with the use of herbal preparations containing black cohosh. Med J Aust 2003; 179:390-391.
100. Barton DL, Loprinzi CL, Quella SK, et al. Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. J Clin Oncol 1998; 16:495-500.
101. Hirata JD, Swiersz LM, Zell B, et al. Does dong quai have estrogenic effects in postmenopausal women? A double-blind, placebo-controlled trial. Fertil Steril 1997; 68:981-986.
102. Chenoy R, Hussain S, Tayob Y, et al. Effect of oral gamolenic acid from evening primrose oil on menopausal flushing. BMJ 1994; 308:501-503.
103. Komesaroff PA, Black CV, Cable V, et al. Effects of wild yam extract on menopausal symptoms, lipids and sex hormones in healthy menopausal women. Climacteric 2001; 4:144-150.
104. Van Patten CL, Olivotto IA, Chambers GK, et al. Effect of soy phytoestrogens on hot flashes in postmenopausal women with breast cancer: a randomized, controlled clinical trial. J Clin Oncol 2002; 20:1449-1455.